Compare MBWM & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBWM | DRTS |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.5M | 978.2M |
| IPO Year | 1997 | N/A |
| Metric | MBWM | DRTS |
|---|---|---|
| Price | $60.40 | $11.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $55.67 | $8.67 |
| AVG Volume (30 Days) | 119.2K | ★ 803.0K |
| Earning Date | 04-21-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | $699.98 |
| P/E Ratio | $44.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.75 | $2.87 |
| 52 Week High | $60.40 | $14.11 |
| Indicator | MBWM | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 64.18 | 45.79 |
| Support Level | $48.89 | $11.51 |
| Resistance Level | N/A | $14.00 |
| Average True Range (ATR) | 1.57 | 0.91 |
| MACD | 0.04 | -0.21 |
| Stochastic Oscillator | 93.34 | 11.79 |
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.